Role and timing of new drugs in CLL
Hematol Oncol
.
2017 Jun:35 Suppl 1:30-32.
doi: 10.1002/hon.2397.
Author
Michael Hallek
1
Affiliation
1
University of Cologne, Cologne, Germany.
PMID:
28591418
DOI:
10.1002/hon.2397
No abstract available
Publication types
Review
MeSH terms
Antineoplastic Agents / therapeutic use*
Disease-Free Survival
Humans
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
Leukemia, Lymphocytic, Chronic, B-Cell / mortality*
Risk Factors
Survival Rate
Time Factors
Substances
Antineoplastic Agents